[Form 4] Twist Bioscience Corporation Insider Trading Activity

Rhea-AI Filing Summary

Patrick John Finn, President and COO of Twist Bioscience Corporation (TWST), reported a non-discretionary sale of 1,840 shares of Twist common stock on 08/21/2025 at a price of $25.964 per share. The filing states these shares were sold solely to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units and were not discretionary trades by the reporting person. After the transaction, the reporting person beneficially owned 233,529 shares, which the filing notes includes shares acquired under the company’s Employee Stock Purchase Plan in an exempt transaction. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Finn on 08/25/2025.

Positive

• Timely and transparent disclosure of the sale and the reason (tax withholding) in a Form 4
• Sale was non-discretionary (sell-to-cover) which reduces the likelihood the trade signals a change in insider conviction

Negative

• None.

Insights

Financial Analyst

TL;DR Routine sell-to-cover for RSU tax withholding; no indication of discretionary selling or material change in ownership.

The reported sale of 1,840 shares was executed at $25.964 per share to satisfy tax withholding tied to RSU vesting. Such transactions are typically administrative and do not reflect a deliberate change in investment stance by the officer. The post-transaction ownership of 233,529 shares remains sizable but the filing provides no details on percentage ownership or changes to compensation structure. For capital markets impact, this disclosure is routine and unlikely to be material to valuation.

Corporate Governance Expert

TL;DR Disclosure aligns with Section 16 reporting requirements; sale designated as non-discretionary "sell-to-cover."

The Form 4 clearly identifies the reporting person, relationship to the issuer, and the nature of the transaction as mandated tax-withholding resulting from RSU vesting. The filing was executed by an attorney-in-fact and includes the required explanatory footnotes about ESPP-exempt shares. From a governance and compliance perspective, the filing meets transparency expectations and shows no red flags such as undisclosed trading plans or late reporting.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Finn Patrick John

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD.

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and COO

3. Date of Earliest Transaction (Month/Day/Year)
08/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/21/2025		S		1,840(1)	D	$25.964	233,529(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

2. Includes shares that were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Patrick John Finn	08/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Patrick John Finn report on the Form 4 for TWST?

The Form 4 reports a sale of 1,840 shares on 08/21/2025 at $25.964 per share to satisfy tax withholding from RSU vesting.

Was the sale by the TWST officer discretionary?

No. The filing states the sale was a mandated "sell-to-cover" to satisfy tax withholding obligations and not a discretionary trade.

How many TWST shares does the reporting person own after the transaction?

The reporting person beneficially owned 233,529 shares following the reported transaction.

Does the Form 4 indicate any other types of transactions or derivative holdings?

No. The filing lists only the non-derivative sale for tax withholding and does not report any derivative transactions.

Who signed the Form 4 and when?

The Form 4 was signed by Kendra Fox as attorney-in-fact for Patrick John Finn on 08/25/2025.